FDA Approves Dupixent for Treatment of Bullous Pemphigoid
The FDA has approved Dupixent for adult patients with bullous pemphigoid, offering a new targeted treatment option based on promising clinical trial results that show improved remission and reduced itch.
The U.S. Food and Drug Administration has granted approval for Dupixent (dupilumab) to be used in treating adult patients suffering from bullous pemphigoid, a chronic autoimmune skin condition characterized by large, tense blisters. The approval was based on compelling results from the ADEPT phase 2/3 clinical trial, which demonstrated significant benefits for patients.
In the study, individuals with moderate-to-severe bullous pemphigoid were randomly assigned to receive either Dupixent 300 mg or a placebo, both added to standard oral corticosteroid therapy. After 36 weeks, 18.3% of those treated with Dupixent achieved sustained disease remission, compared to only 6.1% in the placebo group. Moreover, 38.3% of patients on Dupixent experienced a meaningful reduction in itch severity, a common and distressing symptom, versus 10.5% on placebo. The treatment also allowed for a lower median cumulative dose of oral corticosteroids (2.8 grams with Dupixent vs. 4.1 grams with placebo), indicating a potential to reduce steroid-related side effects.
Patients receiving Dupixent commonly experienced adverse events such as joint pain, conjunctivitis, blurred vision, herpes viral infections, and keratitis. There was also a case of acute generalized exanthematous pustulosis reported. Despite these side effects, experts highlight the importance of this therapeutic advance, especially considering the challenges of managing bullous pemphigoid in elderly populations who often face additional health burdens.
Alyssa Johnsen, M.D., Ph.D., from Sanofi, noted that until now, treatment options for bullous pemphigoid have been limited and often problematic. She emphasized that Dupixent uniquely targets key mechanisms underlying the disease, addressing the type 2 inflammation central to its pathology, which may enable patients to achieve sustained remission and experience less itching.
The approval was a collaborative effort between Sanofi and Regeneron, marking a significant step forward in targeted therapy for autoimmune skin disorders.
For more details, see the original report at MedicalXpress.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Using Tumor Microenvironment Mapping to Predict Lung Cancer Immunotherapy Outcomes
A new study demonstrates how analyzing immune cell arrangements within lung tumors can better predict patient response to immunotherapy, paving the way for more personalized treatment strategies.
Open-Access Dataset from Decade-Long Brain Aging Study Promotes Global Research Efforts
A comprehensive decade-long brain aging study by the University of Texas at Dallas has released an open-access dataset, fostering global research efforts into healthy brain aging and neurodegeneration. This extensive resource includes multimodal imaging and cognitive data from nearly 500 adults, enabling insights into individual aging trajectories and early indicators of decline.
Collaborative Initiative Aims to Enhance Mental Health Diagnosis with Biological Testing
A global coalition is working to revolutionize mental health diagnosis by integrating biological tests such as MRI, blood analyses, and digital tools, aiming for more accurate and personalized psychiatric care in the coming decades.
Wyandotte County, Kansas, Launches Low-Cost Measles Vaccination Initiative to Prevent Outbreak
Wyandotte County in Kansas is increasing access to low-cost measles vaccines amid rising cases in neighboring regions to prevent an outbreak and protect public health.